Efficacy of a Gal-lectin subunit vaccine against experimental Entamoeba histolytica infection and colitis in baboons (Papio sp.)

Vaccine

Volumn 30, Issue 20, 2012, Pages 3068-3075

  Abd Alla, Mohamed D ^a,b   Wolf, Roman ^c   White, Gary L ^c   Kosanke, Stanley D ^c   Cary, David ^c   Verweij, Jaco J ^d   Zhang, Mie Jie ^a   Ravdin, Jonathan I ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b AL AZHAR UNIVERSITY   (Egypt)

^c UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Baboon model; Entamoeba histolytica; Peptide vaccine

Indexed keywords

CHOLERA TOXIN; GALACTOSE INHIBITABLE ADHERENCE LECTIN VACCINE; PEPTIDE VACCINE; UNCLASSIFIED DRUG;

AMEBIASIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; BABOON; COLITIS; COLONOSCOPY; CONTROLLED STUDY; DRUG EFFICACY; ENTAMOEBA HISTOLYTICA; ENZYME LINKED IMMUNOSORBENT ASSAY; FECES ANALYSIS; FEMALE; HISTOPATHOLOGY; NONHUMAN; OUTCOME ASSESSMENT; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; TROPHOZOITE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; CHOLERA TOXIN; DISEASE MODELS, ANIMAL; DYSENTERY, AMEBIC; ENTAMOEBA HISTOLYTICA; ENTAMOEBIASIS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FECES; LECTINS; PAPIO; POLYMERASE CHAIN REACTION; PROTOZOAN VACCINES; VACCINES, SUBUNIT;

EID: 84862830175     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.02.066     Document Type: Article

References (50)

1. Ravdin J.I., Stauffer W.M. Entamoeba histolytica (Amebiasis). Mandell: principles and practice of infectious diseases 2005, 3097-3111. Churchill-Livingstone Inc., New York. fifth and sixth ed. G.L. Mandell, J.E. Bennett, R. Dolin (Eds.).
2. Abd Alla M.D., Jackson T.F.G.H., Rogers T., Reddy S., Ravdin J.R. Mucosal immunity to asymptomatic Entamoeba histolytica and Entamoeba dispar infection is associated with a peak intestinal anti-lectin immunoglobulin a antibody response. Infect Immun 2006, 74:3897-3903.
3. Ravdin J.I., Abd Alla M.D., Welles S.L., Reddy S., Jackson T.F.G.H. Intestinal anti-lectin immunoglobulin A antibody response and immunity to Entamoeba dispar infection following cure of amebic liver abscess. Infect Immun 2003, 71:6899-6905.
4. Haque R., Ali I.M., Sack R.B., Farr B.M., Ramakrishnan G., Petri W.A. Amebiasis and mucosal IgA antibody against Entamoeba histolytica adherence lectin in Bangladeshi Children. J Infect Dis 2001, 183:1787-1793.
5. Blessman J., Van L.P., Nu P.A.T., Thi H.D., Muller-Myhsok B., Buss H., et al. Epidemiology of amebiasis in a region of high incidence of amebic liver abscess in central Vietnam. Am J Trop Med Hyg 2002, 66:578-583.
6. Ramos F., Morán P., González E., García G., Ramiro M., Gomez A., et al. High prevalence rate of Entamoeba histolytica asymptomatic infection in a rural Mexican community. Am J Trop Med Hyg 2005, 73:87-91.
7. Abd Alla M.D., Wahib A.A., Ravdin J.I. Comparison of antigen - capture ELISA to stool-culture methods for the detection of asymptomatic Entamoeba species infection in Kafer Daoud, Egypt. Am J Trop Med Hyg 2000, 62:579-582.
8. Walsh J.A. Problems in diagnosis and recognition of amebiasis: estimation of global magnitude of morbidity and mortality. Rev Infect Dis 1986, 8:228-233.
9. Lösch F. Massenhafte Entwicklung von Amoben in Dickdarm. Virchows Arch f path Anat 1875, 65:196-211.
10. Bundesen H.N., Tonney F.O., Rawlings I.D. The outbreak of amebiasis in Chicago during 1934. JAMA 1934, 102:367-372.
11. Ravdin J.I., Guerrant R.L. Role of adherence in cytopathogenic mechanisms of Entamoeba histolytica: study with mammalian tissue culture cells and human erythrocytes. J Clin Invest 1981, 68:1305-1313.
12. Chadee K., Petri W.A., Innes D.J., Ravdin J.I. Rat and human colonic mucins bind to and inhibit the adherence lectin of Entamoeba histolytica. J Clin Invest 1987, 80:1245-1254.
13. Petri W.A., Smith R.D., Schlesinger P.H., Murphy C.E., Ravdin J.I. Isolation of galactose-binding lectin that mediates the in vitro adherence of Entamoeba histolytica. J Clin Invest 1987, 80:1238-1244.
14. Ragland B.D., Ashley L.S., Vaux D.L., Petri W.A. Entamoeba histolytica: target cells killed by trophozoites undergo DNA fragmentation which is not blocked by Bcl-2. Exp Parasitol 1994, 79:460-467.
15. Ravdin J.I., Moreau F., Sullivan J.A., Petri W.A., Mandell G.L. The relationship of free intracellular calcium to the cytolytic activity of Entamoeba histolytica. Infect Immun 1988, 56:1505-1512.
16. Petri W.A., Chapman M.D., Snodgrass T., Mann B.J., Broman J., Ravdin J.I. Subunit structure of galactose and N-acetyle-d-galactoseamine inhibitable adherence lectin of Entameba histolytica. J Biol Chem 1989, 264:3007-3012.
17. Petri W.A., Ravdin J.I. Protection of gerbils from amebic liver abscess by immunization with the galactose-specific adherence lectin of Entamoeba histolytica. Infect Immun 1991, 59:97-101.
18. Tachibana H., Cheng X.J., Tsukamoto H., Itoh J. Characterization of Entamoeba histolytica intermediate subunit lectin-specific human monoclonal antibodies generated in transgenic mice expressing human immunoglobulin loci. Infect Immun 2009, 77:549-556.
19. Soong G., Kain K.C., Abd Alla M.D., Jackson T.F.G.H., Ravdin J.I. A recombinant cysteine-rich section of Entamoeba histolytica galactose-inhibitable lectin is efficacious as a subunit vaccine in the gerbil model of amebic liver abscess. J Infect Dis 1995, 71:645-651.
20. Lotter H., Rüssman H., Heesemann J., Tannich E. Oral vaccination with recombinant Yersinia enterocolitica expressing hybrid type III proteins protects gerbils from amebic liver abscess. Infect Immun 2004, 72:7318-7321.
21. Zhang T., Cieslak P.R., Stanley S.L. Protection of gerbils from amebic liver abscess by immunization with a recombinant Entamoeba histolytica antigen. Infect Immun 1995, 62:1166-1170.
22. Beving D.E., Soong G., Ravdin J.I. Oral immunization with a recombinant cysteine-rich section of the Entamoeba histolytica galactose-inhibitable lectin elicits an intestinal secretory immunoglobulin A response that has in vitro adherence inhibition activity. Infect Immun 1996, 64:1473-1476.
23. Houpt E., Barroso L., Lockhardt L., Wright R., Cramer C., Lyerly D., et al. Prevention of intestinal amebiasis by vaccination with the Entamoeba histolytica Gal/GalNac lectin. Vaccine 2004, 22:612-618.
24. Guo X., Barroso L., Lyerly D.M., Petri W.A., Houpt E.R. CD4+ and CD8+ T cell- and IL-17-mediated protection against Entamoeba histolytica induced by a recombinant vaccine. Vaccine 2011, 29:772-777.
25. Houpt E.R., Glembocki D.J., Obrig T.G., Moskaluk C.A., Lockhart L.A., Wright R.L., et al. The mouse model of amebic colitis reveals mouse strain susceptibility to infection and exacerbation of disease by CD4 T cells. J Immunol 2002, 169:4496-4503.
26. Duggal P., Guo X., Haque R., Peterson K.M., Ricklefs S., Mondal D., et al. A mutation in the leptin receptor is associated with Entamoeba histolytica infection in children. J Clin Invest 2011, 121:1191-1198.
27. Legesse M., Erko B. Zoonotic intestinal parasites in Papio anubis (baboon) and Cercopithecus aethiops (vervet) from four localities in Ethiopia. Acta Tropica 2004, 90:231-236.
28. Verweij J.J., Vermeer J., Brienen E.A.T., Blotkamp C., Laeijendecker D., van Lieshout L., et al. Entamoeba histolytica infections in captive primates. Parasitol Res 2003, 90:100-103.
29. Jackson T.F.G.H., Sargeaunt P.G., Visser P.S., Gathiram V., Suparsad S., Anderson C.B. Entamoeba histolytica: naturally occurring infections in baboons. Arch Invest Med 1990, 21(Suppl. 1):153-156.
30. Abd Alla M.D., Jackson T.F.G.H., Soong G., Mazinac M., Ravdin J.R. Identification of the Entamoeba histolytica galactose-inhibitable lectin epitopes recognized by human IgA antibodies following cure of amebic liver abscess. Infect Immun 2004, 72:3974-3980.
31. Abd Alla M.D., White G., Rogers T., Cary M., Carey D., Ravdin J.I. Adherence-inhibitory intestinal immunoglobulin A antibody response in Baboons elicited by use of a synthetic intranasal lectin-based amebiasis subunit vaccine. Infect Immun 2007, 75:3812-3822.
32. Gathiram V., Jackson T.F.G.H. Frequency distribution of Entamoeba histolytica zymodemes in a rural South African population. Lancet 1985, i:719-721.
33. Wilmot A.J. Clinical medicine in Africans in Southern Africa 1973, 3-15. Churchill-Livingstone, Edinburgh. G.D. Campbell, Y.K. Seedat, G. Daynes (Eds.).
34. Niesters H.G.M. Clinical virology in real time. J Clin Virol 2002, 25(Suppl. 3):S3-S12.
35. Garfinkel L.I., Giladi M., Huber M., Gitler C., Mirelman D., Revel M., et al. DNA probes specific for Entamoeba histolytica possessing pathogenic and nonpathogenic zymodemes. Infect Immun 1989, 57:926-931.
36. Ravdin J.I., Jackson T.F.G.H., Petri W.A., Murphy C.F., Ungar B.L.P., Gathiram V., et al. Association of serum antibodies to adherence lectin with invasive amebiasis and asymptomatic infection with pathogenic Entamoeba histolytica. J Infect Dis 1990, 162:768-772.
37. Atherton E., Fox H., Harkiss D., Logan C.J., Sheppard R.C., Williams B.J. A mild procedure for solid phase peptide synthesis: use of fluorenylmethoxycarbonylamino-acids. J Chem Soc Chem Commun 1978, 537-543.
38. Kean B.H., Mott K.E., Russel A.J. Tropical medicine and parasitology: classic investigations 1978, Cornell Univ Press, Ithaca, NY.
39. Munene E., Otsyula M., Mbaabu D.A.N., Mutahi W.T., Muriuki S.M.K. Helminth and protozoan gastrointestinal tract (GIT) parasites in captive and wild-trapped African non-human primates. Vet Parasitol 1998, 78:195-201.
40. Walker E.L., Sellards A.W. Experimental entamoebic dysentery. Philipp J Sci (B, Trop Med) 1913, 8:253-331.
41. DuPont H., Hornick R. Adverse effect of Lomotil therapy in shigellosis. JAMA 1973, 226:1525-1528.
42. Stanley S.L., Blanchard J.L., Johnson N., Foster L., Kunz-Jenkins C., Zhang T., et al. Immunogenicity of the recombinant serine rich Entamoeba histolytica protein (SREHP) amebiasis vaccine in the African green monkey. Vaccine 1995, 13:947-951.
43. Amyx A.L., Asher D.M., Nash T.E., Gibbs C.J., Gajdusek B.C. Hepatic amebiasis in spider monkeys. Am J Trop Med Hyg 1978, 27:888-891.
44. Elsdon D.R., Madison S.E. Invasive amebiasis. An attempt at a trigger. S Afr Med J Sci 1964, 61:172-175.
45. Shearer M.H., Stevens F.J., Westholm F.A., Jenson H.B., Chanh T.C., Carey K.D., et al. Serologic cross reactions among primate immunoglobulins. Dev Comp Immunol 1995, 19:547-557.
46. Bernacky B.J., Gibson S.V., Keeling M.E., Abee C. Nonhuman primates. Laboratory animal medicine 2002, 706-710. second ed. J.K. Fox, L.C. Anderson, F.M. Loew, F.W. Quimby (Eds.).
47. Fujihashi K., Koga T., van Ginkel F.W., Hagiwara Y., McGhee J.R. A dilemma for mucosal vaccination: efficacy versus toxicity using enterotoxin-based adjuvants. Vaccine 2002, 20:2431-2438.
48. Aponte J.J., Aide P., Renom M., Mandomando I., Bassat Q., Sacarlal J., et al. Safety of the RTS, S/AS02D candidate malaria vaccine in infants living in a highly endemic area of Mozambique: a double blind randomized controlled phase I/IIb trial. Lancet 2007, 370:1543-1551.
49. Sasaki S., Sumino K., Hamajima K., Fukushima J., Ishii N., Kawamoto S., et al. Induction of systemic and mucosal immune responses to human immunodeficiency virus type 1 by a DNA vaccine formulated with QS-21 saponin adjuvant via intramuscular and intranasal routes. J Virol 1998, 72:4931-4939.
50. de Haan A., Geerligs H.J., Huchshorn J.P., van Scharrenburg G.J.M., Palache A.M., Wilschut J. Mucosal immunoadjuvant activity of liposomes: induction of systemic IgG and secretory IgA responses in mice by intranasal immunization with an influenza subunit vaccine and coadministered liposomes. Vaccine 1995, 13:155-162.